Colorectal Cancer Clinical Trial
Official title:
The Use of Immunochemical Faecal Occult Blood Test (iFOBT) in General Practice. A Randomised Trial of the Implementation of iFOBT.
| Verified date | November 2015 |
| Source | University of Aarhus |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Background
Colorectal cancer (CRC) is common, and a leading cause of cancer death. The evaluation of
patients suspected to have CRC is difficult due to poorly predictive alarm symptoms and many
patients present with uncharacteristic or vague symptoms. The faecal marker of human globin,
iFOBT, could play an important role in aiding the general practitioner in detecting CRC.
Hypothesis
It will be possible to implement iFOBT in general practice as a test performed on patients
who do not fulfill the criteria for fast-track referral for colorectal cancer, but whose
symptoms could indicate an undiagnosed colorectal cancer.
Aim
To implement iFOBT in general practice and evaluate the uptake and clinical use of the test.
Furthermore, we want to investigate the performance of iFOBT when used on patients
presenting with uncharacteristic symptoms of CRC, and the clinical implications.
Materials and methods
The study uses a cluster randomised stepped wedge design. Clusters are constituted by the 18
municipalities in the central Denmark Region, and these are randomised when to receive a
continuous medical education (CME). The date of inclusion is defined as the first working
day in the month the CME is planned to be conducted. The CME is part of an intervention
aimed to facilitate the implementation of iFOBT in general practice. Besides a CME, the
intervention consist of a start package (iFOBT kits, a guideline and online educational
material) that is sent to GPs when they are included in the study, and a status mail that
GPs receive approx. one month after inclusion. The inclusion period is during the first 7
month of the study period, the study lasts for one year.
Perspectives
This study will provide important knowledge on how to improve CRC diagnostics in general
practice.
| Status | Completed |
| Enrollment | 825 |
| Est. completion date | September 2016 |
| Est. primary completion date | September 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - GPs in the Central Denmark Region - Patients >30 years eligible for iFOBT according to guideline Exclusion Criteria: |
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Research Unit for General Practice | Aarhus C |
| Lead Sponsor | Collaborator |
|---|---|
| University of Aarhus |
Denmark,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The rate of positive iFOBTs | 1 year | ||
| Primary | The number of CRCs diagnosed after a positive iFOBT | 1 year | ||
| Primary | The stage distribution of CRCs for patients with a positive iFOBT | UICC stages I-IV | 1 year | |
| Primary | The positive predictive value for detecting colorectal cancer | The risk of having CRC when the iFOBT is positive | 1 year | |
| Primary | The positive predictive value for detecting colorectal cancer in relation to cut-off value of iFOBT | The risk of having CRC at different iFOBT values. | 1 year | |
| Primary | The positive predictive value for detecting colorectal cancer in relation to indications of using iFOBT | The risk of having CRC when iFOBT is positive and specific symptoms. When requesting FIT, the GP register the patients' symptoms. | 1 year | |
| Secondary | The rate of general practices starting to use the iFOBT, stratified for participation in the CME. | The relation between number of general practices started using iFOBT and time. | 1 year | |
| Secondary | The monthly rate of requested iFOBTs, stratified for participation in the CME. | The relation between number of requested iFOBTs and time. | 1 year | |
| Secondary | The monthly rate of positive iFOBTs, stratified for participation in the CME. | The relation between number of positive iFOBTs and time. | 1 year | |
| Secondary | Indications used for requesting iFOBT, stratified for participation in the CME. | 1 year | ||
| Secondary | The rate of referrals in the cancer patient pathway for colorectal cancer | 1 year | ||
| Secondary | The rate of performed colonoscopies | 1 year |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |